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Relationship Between Patient’s Risk Profile and Benefits in Mortality From Adjunctive
Abciximab to Mechanical Revascularization for ST-Segment Elevation Myocardial Infarction:s of Randomized Trialso the Editor: Adjunctive abciximab has been shown to reduce
ortality in patients undergoing mechanical revascularization for
T-segment elevation myocardial infarction (STEMI) (1). The
oal of this study was to investigate, by the use of a meta-
egression analysis of randomized trials, whether the benefits in
ong-term mortality from abciximab administration correlated
ith the patient’s risk profile.
The literature was scanned by formal searches of electronic
atabases (MEDLINE, PubMed) and the scientific session ab-
tracts in Circulation, the Journal of American College of Cardiology,
nd the European Heart Journal from January 1990 to December
004. The following key words were used: randomized trial,
yocardial infarction, reperfusion, primary angioplasty, facilitated
ngioplasty, stenting, glycoprotein IIb/IIIa inhibitors, abciximab.
ll data were extracted by two investigators. Data were managed
ccording to the intention-to-treat principle.
The end point was mortality at 6 to 12 months of follow-up.
tatistical analysis was performed using the Review Manager 4.27
reeware package (Cochrane Collaboration, Oxford, United King-
om), the SPSS 11.5 statistical package (SPSS Inc., Chicago,
llinois), and SAS version 8.2 (SAS Institute Inc., Cary, North
arolina). Odds ratio (OR) and 95% confidence intervals (CIs)
ere used as summary statistics (1).
A fixed-effect meta-regression analysis for the log-odds ratio on
ortality (expressed as odds) of the control group was carried out
y resorting to the Proc MIXED procedure of SAS version 8.2
SAS Institute Inc.) according to the approach proposed by van
able 1. Characteristics of Randomized Trials Included in the M
Study Period n Study-Drug D
APPORT (1) 1995–1997 483 Abciximab* (n  241
DMIRAL (2) 1997–1998 300 Stenting  abciximab
ADILLAC (3) 1997–1999 2,082 Abciximab*  stent (
control  stent (n
SAR-2 (4) 1997–1998 401 Stenting (n  200) v
etronio et al. (5) 1998–2000 89 Abciximab* (n  44)
orman et al. (6) 1998–2001 163 Early (n  56) vs. lat
Abciximab* vs. placeb
CE (7) 2001–2002 400 Stenting (n  200) vouwelingen et al. (2). Results are reported as regression coeffi-
ients with associated 95% CI and two-sided p values. The
stimated meta-regression line was plotted in graph together with
he observed log-odds ratios.
A total of seven randomized trials with available follow-up data
ere analyzed (Table 1), involving 3,918 patients (1,999 in the
bciximab group and 1,919 in the placebo group). In almost all
rials, abciximab was started after initial angiography. Abciximab
as associated with a significant reduction in 6- to 12-month
ortality (4.4% vs. 6.2%, OR [95% CI]  0.69 [0.52 to 0.92],
 0.01, p heterogeneity 0.15). Figure 1 shows the relationship
etween the patient’s risk profile and the benefits from abciximab
dministration in terms of 6- to 12-month mortality (b  9.9
20.1 to 0.21], p  0.053).
The main finding of this meta-analysis is that the mortality
enefits of adjunctive abciximab therapy to mechanical revascular-
zation for ST-segment elevation myocardial infarction are related
o the patient’s risk profile.
The benefits in mortality may be the effects of abciximab in
educing distal embolization and improving myocardial perfusion,
actors known to be determinants of long-term survival (3).
It should be remarked that highly selected non-high-risk
atients are commonly enrolled in randomized trials, whereas
enefits in mortality have been shown mostly in trials enrolling
igh-risk patients. In fact, by using a meta-regression analysis, a
irect correlation was found between the patient’s risk profile and
he benefits from abciximab administration in terms of long-term
nalysis
Long-Term Mortality
(%)
(Number of Patients) Abciximab Control p Value
lacebo (n  242) 4.1 4.5 0.83
151) vs. placebo (n  149) 3.4 7.3 0.13
24) or balloon (n  528),
2) or balloon (n  518)
4.2 4.4 0.83
iximab*  stenting (n  201) 6.0 8.5 0.33
lacebo (n  45) 4.5 13.3 0.15
stangiography; n  56)
 51)
4.5 13.7 0.036
iximab*  stenting (n  200) 5.0 10.5 0.04eta-A
esign
) vs. p
* (n 
n  5
 51
s. abc
vs. p
e (po
o (n
s. abcN Engl J Med 2001;344:1895–903. (3) N Engl J Med 2002;346:957–66. (4) J Am
0:533–6. (7) Circulation 2004;109:1704–6.
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February 7, 2006:683–91ortality. Furthermore, several non-randomized studies have
hown significantly better survival in patients with cardiogenic
hock treated with primary angioplasty and abciximab (4).
Recent investigations have shown that time to treatment is a
elevant issue in primary angioplasty and has a significant impact
n mortality (5). Therefore, early administration of pharmacologic
herapy may improve earlier reperfusion with subsequent smaller
nfarct size and better clinical outcome, particularly in high-risk
atients and when long-distance transportation is required. In the
ajority of the trials, abciximab was given just before the angio-
lasty procedure. Only a few and small randomized trials have been
onducted so far to investigate the role of early abciximab admin-
stration during transportation. Data from large ongoing random-
zed trials hopefully will clarify this relevant issue, particularly in
igh-risk patients.
This meta-analysis shows a direct correlation between the patient’s
isk profile and the benefits in mortality from abciximab administra-
ion as an adjunctive therapy to mechanical revascularization for
igure 1. Fixed-effect meta-regression analyses for the log-odds ratio (ln
R) on mortality (expressed as odds) of the control group at 6- to
2-month follow-up. Negative values of the ln OR (y axis) mean more
enefits in mortality associated with abciximab administration, whereas the
ortality rate of the control group (x axis) represents the risk profile of the
atient population included in each trial. The size of the circle corresponds
o the inverse variance of the log-odds ratio, and thus is related to the
tatistical weight of the study.With Functionally Normal Heart: Myocardial
nvolvement even in Duchenne muscular dystrophy (DMD) chil-
d
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cngioplasty, particularly in high-risk patients, that may be identified
y the use of validated risk scores for STEMI (6).
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Integrated Backscatter in Becker Muscular Dystrophy Patients
Ultrasound Tissue Characterization Studyo the Editor: Becker muscular dystrophy (BMD) is an allelic
-linked recessive disorder characterized by an in frame deletion
ncompassing one or more exons of the dystrophin gene, with a
arge phenotypic spectrum, ranging between severe childhood-
nset muscular disease to asymptomatic cases. Cardiac involve-
ent (leading to cardiomyopathy and heart failure) is frequent,
ge-dependent, and unpredictable (1). Since there is no direct
elationship between severity of skeletal and cardiac involvement,
ardiomyopathy frequently develops in patients with normal skel-
tal muscle function (2).
Recently, we showed that ultrasound tissue characterization
UTC) of myocardium is able to detect widespread signs of cardiacren with normal electrocardiographs (ECGs) and left ventricular
ystolic function (3). This surprising observation lead to the
ypothesis that UTC may be a useful tool in assessing early
yocardial involvement in patients with other genetic diseases
ausing structural changes of myocardium (4). To further explore
his hypothesis, we performed UTC analysis in a group of 34
MD patients with no cardiac symptoms (ages 4 to 33 years, mean
7 10 years), all with normal ECGs, left ventricular diastolic and
ystolic function, and segmental wall motion at baseline two-
imensional echocardiography, and in 34 healthy age-matched
ontrol subjects. The diagnosis of BMD was confirmed by mus-
ular biopsy in all cases. None of the patients was under pharma-
ological treatment.
